No Data
No Data
Hisun Pharmaceutical's Parent Nominates Candidate for Chairman
Hisun Pharmaceutical to Pay Additional Taxes Worth 18 Million Yuan
Zhejiang Hisun Pharmaceutical (600267.SH): Received a letter from the controlling shareholder recommending a candidate for the chairman of the board.
Galunhui, September 30th, zhejiang hisun pharmaceutical(600267.SH) announced that it has received a letter from the controlling shareholder zhejiang hisun group co., Ltd. recommending Xiao Weihong as a candidate for the chairman of zhejiang hisun pharmaceutical co., Ltd. Board of Directors for the ninth session of the company.
zhejiang hisun pharmaceutical (600267.SH): total tax payment of 18.0744 million yuan
On September 30, GeLongHui announced that zhejiang hisun pharmaceutical (600267.SH), after self-inspection, needs to make up a total of 15.4723 million yuan in various taxes such as corporate income tax and value-added tax, and needs to pay a penalty of 2.6021 million yuan, totaling 18.0744 million yuan. As of the date of this announcement, the company has paid the above-mentioned taxes and penalties as required.
China Approves Hisun Pharmaceutical's Aspergillosis Tablets
zhejiang hisun pharmaceutical (600267.SH): Posaconazole enteric-coated tablets obtained pharmaceutical registration certificate
On September 26, GeLongHui reported that Zhejiang Hisun Pharmaceutical (600267.SH) recently received the 'Drug Registration Certificate' for the approval of Posaconazole enteric-coated tablets issued by the National Medical Products Administration. Posaconazole enteric-coated tablets are mainly used for the treatment of invasive aspergillosis in adult patients, suitable for preventing the increased risk of invasive aspergillus and candida infections in patients aged 13 and above with severe immunodeficiency, such as patients who develop graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT) or patients with hematologic malignancies who experience prolonged neutropenia due to chemotherapy.
No Data
No Data